IL18 and chronic graft versus host disease: IL-18 exerts its therapeutic effects on chronic GVHD through a tripartite mechanism: it induces donor-versus-host CD8+ CTLs, down-regulates MHC class II expression in host B cells, and reduces the population of donor CD4+ T cells [138].